本次药品捐赠聚焦当地群众卫生健康需求，涵盖了包括对乙酰氨基酚泡腾片、氨咖黄敏胶囊、复方氨酚烷胺片、复方金银 花颗粒在内的4类急需常用药品，总价值人民币59.49万元。这些药品将精准发放至1147户农牧民家庭，有效补充基层医疗卫生 资源，为当地村民的健康保驾护航。 在为基层群众送去健康保障的同时，吉林敖东也始终锚定中医药传承创新的发展方向，稳步推进产业升级。在中医药传承 创新的浪潮中，吉林敖东以科技创新为核心引擎，以标准建设为重要抓手，走出了一条兼具传统特色与现代气息的中医药产业 发展之路。 在科技创新层面，吉林敖东聚焦中药材核心物质基础研究，布局抗衰与再生医学前沿领域，推动中医药从"经验传 承"向"科学解码"跨越。吉林敖东深度挖掘传统中药材的现代科研价值，其相关研究证实，部分中药材活性成分在抗衰、神经 保护、骨骼修复等方面展现出巨大潜力。依托这些研究成果，吉林敖东成功斩获两项重磅发明专利，推动核心产品从传统功效 定位，升级至前沿赛道，精准对接高品质健康消费需求。 同时，吉林敖东以新质生产力赋能中医药全产业链智能化升级。在产业链前端，运用分子辅助育种等生物技术优化药材种 源性状，引入智能化管理系统，实现种植、养 ...

为进一步确保重点品种双蚁复方感冒灵颗粒核心原材料野菊花质量稳定，同时学习和引进湖北金鹰的野 菊花标准化种植技术，12月21日，广西双蚁药业有限公司董事长王波、副总经理陈才安一行赴湖北金鹰 农业发展有限公司，就野菊花良种繁育、规模化种植及加工等全产业链环节展开实地考察调研，为双方 后续深度合作奠定坚实基础。 考察期间，王波董事长一行先后深入湖北金鹰农业野菊花良种繁育中心、标准化种植基地及现代化加工 厂房，通过现场观摩、交流问询等方式，详细了解野菊花种质资源圃运营、良种选育技术攻关、规模化 种植管理模式及产地加工全流程。湖北金鹰农业先进的生产设备、完善的产业链布局和严格的质量控制 体系，给考察团留下深刻印象，得到了高度赞叹。 湖北金鹰农业发展有限公司作为湖北省农业产业化省级重点龙头企业，拥有2580亩道地中药材种植基 地，其中野菊花种植规模达1030亩，还建有20亩野菊花种质资源圃、100亩种源基地及200亩种苗基地， 其种源基地采收的种子可供应全国数万亩野菊花种植；同时在湖北多县市推广种植野菊花超5万亩，形 成了集科研、育苗、种植、加工、销售于一体的完整产业链。此外，公司多年来深耕中药材产业，与华 润三九（00 ...

Core Insights - The company reported a total revenue of 2.61 billion yuan in 2024, a decrease of 24.31% compared to 2023, which had a revenue of 3.45 billion yuan [1] - The pharmaceutical sector remains the main revenue driver, contributing 1.88 billion yuan, accounting for 72.11% of total revenue, despite a 27.83% decline from the previous year [1][3] - The company is focusing on key products in its traditional Chinese medicine segment, which includes core products like Anshen Bnna Liquid and Xiaor Chai Gui Oral Liquid, driving significant revenue [3] Revenue Breakdown by Sector - Pharmaceutical revenue: 1,882,395,047.83 yuan (72.11%), down 27.83% from 2,608,458,378.94 yuan [1] - Chain pharmacy wholesale and retail: 391,365,987.46 yuan (14.99%), up 4.36% from 375,020,113.62 yuan [1] - Other business income: 73,862,569.09 yuan (2.83%), up 62.06% from 45,577,260.70 yuan [1] Product Performance - Traditional Chinese medicine sales: 1,605,541,287.90 yuan (61.50%), down 25.42% from 2,152,662,657.59 yuan [1] - Chemical drugs revenue: 276,853,759.93 yuan (10.61%), down 39.26% from 455,795,721.35 yuan [1] - Health products sales reached 2.12 billion yuan, accounting for 8.13% of total revenue [4] Regional Performance - Northeast region: 968,305,996.09 yuan (37.09%), down 14.76% from 1,135,942,714.05 yuan [1] - North region: 377,546,862.16 yuan (14.46%), up 39.78% from 270,101,901.70 yuan [1] - South region: 330,176,089.26 yuan (12.65%), down 20.40% from 414,786,414.20 yuan [1] Sales Strategy and Growth - The company is enhancing its online sales through platforms like JD, Taobao, and Pinduoduo, while also implementing O2O business models in physical stores [4] - The chain pharmacy segment added 183,000 new members, bringing the total to 1.19 million members [3] - The company closed 11 stores and opened 17 new ones, ending the reporting period with a total of 190 stores [3]